Table 2. Characteristics of Patients Included in the Prospective Meta-analysis.
| DEXA-COVID 19 | CoDEX | RECOVERY | CAPE COVID | COVID STEROID | REMAP-CAPa | Steroids-SARIb | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steroid | No steroid | Steroid | No steroid | Steroid | No steroid | Steroid | No steroid | Steroid | No steroid | Steroid | No steroid | Steroid | No steroid | |
| Patients randomized by June 9, 2020 | 7 | 12 | 128 | 128 | 324 | 683 | 76 | 73 | 15 | 14 | 105 | 92 | 24 | 23 |
| Age, median (IQR), y | 62 (48-68) | 60 (52-69) | 62 (50-70) | 64 (57-73) | 59 (52-66) | 60 (52-68) | 63 (52-71) | 66 (54-73) | 57 (52-75) | 62 (55-71) | 59 (53-68) | 62 (50-72) | 67 (61-74) | 62 (54-68) |
| Female sex, No. (%) | 3 (42.9) | 3 (25) | 47 (36.7) | 44 (34.4) | 91 (28.1) | 182 (26.6) | 22 (28.9) | 23 (31.5) | 2 (13.3) | 4 (28.6) | 30 (28.6) | 25 (27.2) | 7 (29) | 5 (22) |
| PCR-confirmed SARS-CoV-2 infection, No. (%) | 7 (100) | 12 (100) | 120 (93.8) | 122 (95.3) | 301 (92.9) | 647 (94.7) | 72 (94.7) | 72 (98.6) | 15 (100) | 14 (100) | 80 (76.2) | 75 (81.5) | 24 (100) | 23 (100) |
| Treatments at randomization, No. (%) | ||||||||||||||
| Mechanical ventilation | 7 (100) | 12 (100) | 128 (100) | 128 (100) | 324 (100) | 683 (100) | 62 (81.6) | 59 (80.8) | 7 (46.7) | 8 (57.1) | 68 (64.8) | 49 (53.3) | 13 (54) | 14 (61) |
| Vasoactive | 3 (42.9) | 7 (58.3) | 83 (65.4) | 88 (68.8) | Not recorded | Not recorded | 18 (23.7) | 13 (17.8) | 5 (33.3) | 5 (35.7) | 46 (43.8) | 27 (29.3) | 14 (58) | 18 (78) |
| Any antiviralc | 6 (86) | 10 (83) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 24 (100) | 23 (100) |
| Remdesivir | Not recorded | Not recorded | 0 | 0 | 1 (0.3) | 0 | 1 (1.3) | 0 | 0 | 4 (28.6) | 1 (1.0) | 0 | Not recorded | Not recorded |
| Lopinavir or ritonavir | Not recorded | Not recorded | 0 | 1 (0.8) | 0 | 0 | 8 (10.5) | 9 (12.3) | 0 | 0 | 0 | 2 (2.2) | Not recorded | Not recorded |
| Favipravir | Not recorded | Not recorded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Not recorded | Not recorded |
| Hydroxychloroquine | 7 (100) | 12 (100) | 30 (23.4) | 22 (17.2) | 0 | 0 | 29 (38.2) | 32 (43.8) | 1 (6.7) | 0 | 5 (4.8) | 2 (2.2) | 0 | 0 |
| Azithromycin | 0 | 0 | 83 (64.8) | 81 (63.3) | 59 (18.2) | 81 (11.9) | 19 (25.0) | 24 (32.9) | Not recorded | Not recorded | 9 (8.6) | 6 (6.5) | Not recorded | Not recorded |
| Convalescent plasma | 0 | 0 | Not recorded | Not recorded | 0 | 0 | 0 | 0 | 0 | 2 (14.3) | 0 | 0 | Not recorded | Not recorded |
Abbreviations: CAPE COVID, Community-Acquired Pneumonia: Evaluation of Corticosteroids in Coronavirus Disease; CoDEX, COVID-19 Dexamethasone; COVID STEROID, Hydrocortisone for COVID-19 and Severe Hypoxia; DEXA-COVID 19, Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19; IQR, interquartile range; NA, not applicable; PCR, polymerase chain reaction; RECOVERY, Randomized Evaluation of COVID-19 Therapy; REMAP-CAP, Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Steroids-SARI, Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure.
Missing substantial data on antiviral use.
Missing data on PCR results.
Some of the trials did not provide information on individual antiviral drugs, which is indicated by “not recorded.” The trials with NA is this row provided data on individual antiviral drugs in the rows below.